UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN

International review of cell and molecular biology, 2022, Vol.366, p.83-124

2022

Volltextzugriff (PDF)

MPN-100 High Rate of Disease Progression in Patients With Low-Risk Myelofibrosis (MF) Enrolled in the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S413-S413

2024

Volltextzugriff (PDF)

MPN-527 Selinexor and Ruxolitinib Impact on Symptom Burden in Patients With Myelofibrosis Is Potentially Driven by Inhibition of NF-κB and Activation of P53 Pathways

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S437-S438

2024

Volltextzugriff (PDF)

MPN-239 Clinico-Molecular Risk Stratification in 284 Patients With Pre-Fibrotic and Overt Myelofibrosis

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S424-S424

2024

Volltextzugriff (PDF)

MPN-203 Anemia Burden in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): Data From the Veterans Affairs Corporate Data Warehouse (VACDW)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S422-S422

2024

Volltextzugriff (PDF)

MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S390-S390

2023

Volltextzugriff (PDF)

MPN-138 Hematuria in Adult Hemophilic Individuals: Is It the Only Cause of Hemophilia? A Single-Center Experience

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S384-S384

2023

Volltextzugriff (PDF)

Accelerated and blast phase myeloproliferative neoplasms

Best practice & research. Clinical haematology, 2022-06, Vol.35 (2), p.101379-101379, Article 101379

2022

Volltextzugriff (PDF)

MDS/MPN Overlap Syndromes

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S22-S22

Padron, Eric

2024

Volltextzugriff (PDF)

MPN-374 The First Results of Ruxolitinib Versus Best Available Therapy for Polycythemia Vera in Mongolia

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S430-S430

2024

Volltextzugriff (PDF)

MPN-220 Myelofibrosis Treatment Beyond Ruxolitinib: A Single-center Experience With Momelotinib and Pacritinib

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S422-S423

2024

Volltextzugriff (PDF)

MPN-652 Long-Term Response to Selinexor in Patients With Myelofibrosis and Refractory or Intolerant to JAK Inhibitors: Follow-Up Results of a Single-Center, Phase II, Investigator-Initiated Trial (IIT)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S441-S441

2024

Volltextzugriff (PDF)

MPN-470 Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S434-S434

2024

Volltextzugriff (PDF)

Extended Abstract: Accelerated Phase Myelofibrosis

Clinical lymphoma, myeloma and leukemia, 2018-09, Vol.18, p.S40-S42

2018

Volltextzugriff (PDF)

MPN-244: Comorbid Conditions Occur Frequently and Correlate with Early Disease Progression and Poor Outcomes in Young Patients with Myelofibrosis

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S358-S358

2021

Volltextzugriff (PDF)

Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)

Leukemia research, 2023-08, Vol.131, p.107340-107340, Article 107340

2023

Volltextzugriff (PDF)

MPN-580 Evaluation of the Venous Thromboembolism (VTE) in Patients With Myeloproliferative Neoplasm

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S439-S439

2024

Volltextzugriff (PDF)

MPN-409 Associations of JAK2 Mutant Allele Burden With Occurrence of CKD (Chronic Kidney Disease) and Dynamics of Kidney Function Over Time in Patients With Chronic Myeloproliferative Neoplasms

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S394-S394

2023

Volltextzugriff (PDF)

MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S402-S403

2023

Volltextzugriff (PDF)

MPN-339 Outcomes of Patients With Myelofibrosis and Elevated Peripheral Blood Blasts Treated With Pacritinib on Phase II/III Trials

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S389-S390

2023

Volltextzugriff (PDF)

MPN-556 Treatment Comparison of Hydroxyurea vs Ruxolitinib in Essential Thrombocythemia (ET): A Matched Cohort Analysis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S403-S403

2023

Volltextzugriff (PDF)

Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients

Hematology (Luxembourg), 2023-12, Vol.28 (1), p.2280731-2280731

2023

Volltextzugriff (PDF)

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms

Cancers, 2023-07, Vol.15 (15), p.3815

2023

Volltextzugriff (PDF)

MPN-099 Characteristics of Patients With Myelofibrosis and Essential Thrombocythemia Who Harbor a Calreticulin (CALR) Gene Mutation: Subanalysis of the MOST Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S412-S413

2024

Volltextzugriff (PDF)

How COVID-19 and the Dutch ‘intelligent lockdown’ change activities, work and travel behaviour: Evidence from longitudinal data in the Netherlands

Transportation research interdisciplinary perspectives, 2020-07, Vol.6, p.100150-100150, Article 100150

2020

Volltextzugriff (PDF)

1 – 25 von 1.442

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.237)
Mit Volltextzugriff
(1.258)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(879)
Life Sciences & Biomedicine
(798)
Mpn
(723)
Humans
(374)
Hematology
(243)
Oncology
(217)
Mutation
(206)
Myelofibrosis
(172)
Myeloproliferative Neoplasms
(155)
Biological And Medical Sciences
(151)
Microbiology
(137)
Fundamental And Applied Biological Sciences. Psychology
(131)
Female
(125)
Animals
(120)
Male
(120)
Polycythemia Vera
(111)
Physical Sciences
(107)
Myeloproliferative Disorders - Genetics
(105)
Tumors
(103)
Most Probable Number
(102)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN

MPN-100 High Rate of Disease Progression in Patients With Low-Risk Myelofibrosis (MF) Enrolled in the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

MPN-527 Selinexor and Ruxolitinib Impact on Symptom Burden in Patients With Myelofibrosis Is Potentially Driven by Inhibition of NF-κB and Activation of P53 Pathways

MPN-239 Clinico-Molecular Risk Stratification in 284 Patients With Pre-Fibrotic and Overt Myelofibrosis

MPN-203 Anemia Burden in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): Data From the Veterans Affairs Corporate Data Warehouse (VACDW)

MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

MPN-138 Hematuria in Adult Hemophilic Individuals: Is It the Only Cause of Hemophilia? A Single-Center Experience

Accelerated and blast phase myeloproliferative neoplasms

MDS/MPN Overlap Syndromes

MPN-374 The First Results of Ruxolitinib Versus Best Available Therapy for Polycythemia Vera in Mongolia

MPN-220 Myelofibrosis Treatment Beyond Ruxolitinib: A Single-center Experience With Momelotinib and Pacritinib

MPN-652 Long-Term Response to Selinexor in Patients With Myelofibrosis and Refractory or Intolerant to JAK Inhibitors: Follow-Up Results of a Single-Center, Phase II, Investigator-Initiated Trial (IIT)

MPN-470 Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia

Extended Abstract: Accelerated Phase Myelofibrosis

MPN-244: Comorbid Conditions Occur Frequently and Correlate with Early Disease Progression and Poor Outcomes in Young Patients with Myelofibrosis

Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)

MPN-580 Evaluation of the Venous Thromboembolism (VTE) in Patients With Myeloproliferative Neoplasm

MPN-409 Associations of JAK2 Mutant Allele Burden With Occurrence of CKD (Chronic Kidney Disease) and Dynamics of Kidney Function Over Time in Patients With Chronic Myeloproliferative Neoplasms

MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1

MPN-339 Outcomes of Patients With Myelofibrosis and Elevated Peripheral Blood Blasts Treated With Pacritinib on Phase II/III Trials

MPN-556 Treatment Comparison of Hydroxyurea vs Ruxolitinib in Essential Thrombocythemia (ET): A Matched Cohort Analysis

Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms

MPN-099 Characteristics of Patients With Myelofibrosis and Essential Thrombocythemia Who Harbor a Calreticulin (CALR) Gene Mutation: Subanalysis of the MOST Study

How COVID-19 and the Dutch ‘intelligent lockdown’ change activities, work and travel behaviour: Evidence from longitudinal data in the Netherlands

Suchergebnisse filtern